Ellen Gielen
CMSEllen Gielen and Gertie Lintjens jointly head CMS‘ practice, which is known for advising on M&A, contentious reimbursement matters, and pricing negotiations. The 'very knowledgeable' Gielen has extensive experience in handling regulatory cases, often involving pharmaceutical and medical device issues, while Lintjens is well versed in handling R&D projects and early access matters involving pharma products. Judith Kok has a solid track record in assisting with biocides matters and distribution issues. Murat Duman joined the group in January 2024.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘One of the most broad life sciences teams in the Netherlands covering all aspects of life sciences.’
‘Ellen Gielen has seen it all and thus has both the professional knowledge to help clients achieve their goals as well as the gravitas to guide you there.’
‘Ellen Gielen is great and very knowledgeable. I also enjoy working with Judith Kok.’
Key clients
- Amgen
- Boston Scientific
- Brocacef
- Carl Zeiss
- Eli Lilly
- Essity
- Johnson & Johnson
- LEO Pharma
- Mölnlycke Health Care
- Netherlands Cancer Institute
- Nordmark Pharma GmbH
- Pharming Group N.V.
- Sanquin
- Stryker
- Thermo Fisher
- Vivus
Work highlights
- Represented Eli Lilly in litigation concerning reimbursement of its breast cancer treatment Verzenios.
- Advised Carl Zeiss Meditec AG on its agreement to acquire DORC from investment firm Eurazeo SE for EUR 985 million.
- Advising Boston Scientific on the development of a logistics center in the Netherlands.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
The lawyer(s) leading their teams.
Ellen Gielen, Gertie Lintjens